Substituted benzo[d][1,3]dioxoles as BTK and/or JAK3 kinase inhibitors

A compound of formula (I):

• or a pharmaceutically acceptable salt or stereoisomer thereof,
• wherein:
• A represents —NHC(O)—, —NHC(O)CH2—, —NHS(O)2—, —O—, or —S—;
• R1 represents:
• Y1 represents CR5 or N;
• Y2 represents CR5 or N;
• Y3 represents CR5 or N;
• Y4 represents CR5 or N;
• each R5 independently represents H, F, Cl, Br, I, CN, CH3, CF3, OH, OCH3, or OCF3;
• Z represents —NR6—, —O—, or —S—;
• R6 represents H, CH3, CH2CH3, or cyclopropyl;
• each R4 independently represents H, F, Cl, Br, I, CN, NO2, C1-C6 alkyl, CF3, C(O)NH2, C(O)NHCH3, C(O)NHCH2CF3, NH2, NHC1-C6 alkyl, NHC(O)CH3, N(CH3)2, N(CH2CH3)2, OH, OC1-C6 alkyl, OCF3, OCH2CH2OCH3, pyrrolidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, morpholin-4-yl, or phenyl;
• X represents CH or N;
• m represents 0 or 1;
• n represents 0 or 1;
• R2 represents H, Cl, Br, or CN;
• and
• R3 represents H, C1-C6 alkyl, or C2-C6 heterocycloalkyl;
• wherein the C2-C6 heterocycloalkyl is a saturated 4-, 5-, or 6-membered ring containing one, two, or three heteroatoms or heteroatomic groups independently selected from the group consisting of N, NH, O, and S;
• and
• wherein the C1-C6 alkyl or C2-C6 heterocycloalkyl is substituted with one or more substituents independently selected from the group consisting of NH2, NHCH3, NHC(O)CH3, OH, and OCH3.